In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Akero Therapeutics (AKRO – Research Report), with a price target of $35.00. The company’s ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The 20th century was replete with brightly colored Depression glass. Once an affordable necessity, it's now a lively way to ...
You really can't beat the vibrant beauty of Depression glass, so it's no wonder it's such a hit with collectors and anyone ...
Akero Therapeutics, Inc. is headquartered in South San Francisco, CA, and this firm is focused on the development of therapies that restore metabolic balance and improve overall health. The stock ...
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product ...
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by ...
WASHINGTON −The Army Green Beret suspected of triggering an ... in Las Vegas had been receiving mental health treatment for depression as recently as December, a U.S. official said on Friday.
New Delhi: The imposition of anti-dumping duty on solar glass last month has led to a rise ... However, completion of green power projects has gained momentum in the current financial year as ...
Roche Holding AG Akt-0.90% CHF214.52B ...